Moderna said in a statement that it would be able to deliver about 500 million doses a year and possibly up to 1 billion doses per year, starting in 2021.
Last Wednesday, the American-German BioNTech/Pfizer pharmaceutical alliance announced that the USA government had committed US$1.95 billion to procure 100 million doses of its eventual vaccine.
Stéphane Bancel, Moderna's chief executive, told CNBC that he estimated the vaccine had a 75% chance of meeting the US Food and Drug Administration's requirement of being 50% effective.
According to the researchers, the mRNA-1273 vaccine candidate will be tested at approximately 89 clinical research sites in the United States, 24 of which are part of the NIH Coronavirus Prevention Network (CoVPN). Recently, Tech Times learned the USA government has doubled its investment in Moderna's vaccine candidate and committed $472 million in support of the large trial. Fast-forward into July 27th, and the very first of several vaccines are beginning the clinical testing phase: the mRNA vaccine candidate of Moderna. "We're optimistic, cautiously optimistic", Moderna President Dr Stephen Hoge said. Its primary endpoints will be prevention of COVID-19 in those who have not been infected by SARS-CoV-2 prior to immunisation, and prevention of COVID-19 regardless of whether participants have previously been infected by SARS-CoV-2. The network is a part of "Operation Warp Speed", a partnership led by the U.S. Department of Health and Human Services to invest in and coordinate the development, manufacturing and distribution of COVID-19 diagnostics, therapeutics and vaccines.
There's still no guarantee that the experimental vaccine, developed by the National Institutes of Health and Moderna, will really protect the participants.
Moderna's vaccine is based on cutting-edge but unproven technology, which uses a strand of mRNA to instruct the patient's body to make copies of the "Spike" protein found on the surface of the SARS-CoV-2 coronavirus that causes COVID-19. These vaccines, though relatively new, immunize against viruses and can be manufactured quicker than traditional vaccines that trigger immune response by generally through dead viruses of the disease.
- England in control of decider
- John Lewis to lie in state at U.S. Capitol
- Will there be a Kissing Booth 3?
- Mick Fleetwood Remembers Late Bandmate Peter Green in Heartfelt Tribute
- New Galaxy Note 20 Leak Shows the S Pen’s Magic Wand Abilities
- One killed, dozens hurt in renewed USA clashes
- British PM Boris Johnson says COVID-19 struggle was worsened by obesity
- Harry, Meghan Distance Themselves From Book On Time In Royal Family
- 'folklore' by Taylor Swift sells over 1.3 million copies in 24 hours
- United Nations rights body urges USA to rein in police at protests